ADMET Products and Services – Your Guide to Trends and Revenue Potentials The pharma ADMET testing market gains much interest from pharmaceutical companies as they look to implement more-predictive ADMET testing. That finding and many others appear in a new report by Visiongain.
Absorption, distribution, metabolism, excretion and toxicology (ADMET) testing is an integral part of drug development. Visiongain estimates the ADMET testing market was valued at $5.80bn in 2014, with the majority of revenues being attributed to in vitro testing.
Our new report gives you 51 tables, 48 charts and three interviews. Discover the most lucrative areas in that industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market, submarket and national level. You will see financial results, interviews, trends, opportunities, and revenue predictions for those pharma R&D technologies. There is much opportunity in that fast moving market.
Forecasts from 2015-2025 and other analyses show you commercial prospects Besides revenue forecasting to 2025, our new study provides you with recent results, growth rates, and market shares. Discover qualitative analyses (including SWOT analysis) and commercial developments. Commercial drivers and restraints for each submarket are also provided, as are revenue forecasts to 2025. • In vitro ADMET testing • In vivo ADMET applications • In silico ADMET uses.
Our new study predicts the pharma ADMET testing market will expand throughout the forecast period, 2015 to 2025, driven by increased demand for that screening and advances in technology enhancing the reliability and predictive capabilities of those assays.
Leading companies and potential for market growth Overall revenue for the pharma ADMET testing market will reach $10.51bn in 2019, our work forecasts. We predict strong revenue growth through to 2025, as drug developers select stronger product candidates for development, using ADMET technology.
Our work also analyses prominent companies in that market. See Visiongain’s analysis of leading companies, including these: • Agilent Technologies • BIOVIA • Cyprotex • Bio-Rad Laboratories • Quintiles • CMIC • Charles River Laboratories • WuXi PharmaTech • Promega Corporation • Sigma-Aldrich.
A company profile gives you the following information where available: • Recent historical revenues • Discussion of a company’s activities, technologies and outlook • Brief assessment of the company’s ADMET strategy.
With that information you will assess competitors’ capabilities, progress, and commercial prospects, helping you stay ahead and benefit your reputation for insight.
National markets for those drug development technologies Our study shows you prospects for ADMET sales in developed and developing countries. You will see individual revenue forecasts to 2025 for 12 countries: • United States • Japan • Germany, France, United Kingdom, Italy and Spain (EU5) • Brazil, Russia, India and China (BRIC) • South Korea.
With our analysis you will investigate regions with highest revenues, demand and potential sales. Explore progress, needs and opportunities, seeing how you can gain.
What forces affect the pharma ADMET testing industry? Our new report discusses issues and events affecting the pharmaceutical ADMET testing industry and market. You will find discussions, including qualitative analyses: • Rising demand for early ADMET testing • Developments in that drug screening technology.
You will see discussions of technological, commercial, and economic issues, with emphasis on the competitive landscape and business outlooks. Discover what the future holds.
How Pharma ADMET Testing: World Industry and Market Prospects 2015-2025 helps In particular, our new investigation gives the following knowledge to benefit your work: • Revenue forecasts to 2025 for the pharma ADMET testing market – discover that industry’s commercial prospects, finding what revenues and growth are possible • Revenue forecasts to 2025 for three submarkets – explore sales potentials of in vitro, in vivo and in silico testing • Revenue forecasts to 2025 for 12 leading national markets – US, EU5 (Germany, France, UK, Italy and Spain), Japan, Brazil, Russia, India, China and South Korea • Assessment of leading companies – assess competitors, exploring their product and service portfolios, strategic developments and commercial outlooks • Exclusive interviews with three companies – gain opinions from MultiCASE Inc., Optivia Biotechnology and Takara Bio Europe AB, seeing what participants say and do • Discussion of what stimulates and restrains companies and the market – examine forces affecting those technologies and their providers • Prospects for established firms and those seeking to enter the industry – discover what the future holds, helping you stay ahead in knowledge.
There you will find quantitative and qualitative analyses with independent predictions. That way you will receive information that only our report contains, staying informed on business intelligence.
Data and discussions found nowhere else, helping your research, analyses and decisions With our survey you are less likely to fall behind in knowledge or miss opportunity. See how you could benefit your research, analyses, and decisions. Also see how you can save time and receive recognition for commercial insight.
Visiongain’s new study is for everybody needing analyses of the pharma ADMET testing market and that industry’s leading companies. There you will find data, trends and predictions. Stay ahead by getting that report here now.
Visiongain is a trading partner with the US Federal Government CCR Ref number: KD4R6
1. Report Overview 1.1 Overview of the World Market for ADMET Testing 1.2 Why You Should Read This Report 1.3 How This Report Delivers 1.4 Main Questions Answered by This Analysis 1.5 Who Is This Study For? 1.6 Methods of Research and Analysis 1.7 Frequently Asked Questions (FAQs) 1.8 Some Associated Reports 1.9 About Visiongain
2. An Introduction to ADMET Testing 2.1 What Is ADMET Testing? 2.1.1 Absorption 2.1.2 Distribution 2.1.3 Metabolism 2.1.3.1 MIST Guidelines 2.1.4 Excretion 2.1.5 Toxicology 2.2 The Role of ADMET Testing in Biosimilarity 2.3 Trial Design and Execution 2.3.1 Phases of Drug Development 2.3.1.1 Phase 0 Trials: Establishing Pharmacodynamic and Pharmacokinetic Properties 2.3.1.2 Phase I Trials: First-In-Human Studies 2.3.1.3 Phase II Trials: Proof-Of-Concept 2.3.1.4 Phase III Trials: Preparing for Approval Applications 2.3.1.5 Post-Marketing Studies 2.3.2 Reducing Attrition Rates in Drug Development through Predictive ADMET 2.3.3 Benefits of Outsourcing
3. ADMET Testing: World Market 2015-2025 3.1 Pharma R&D Expenditures by Phase, 2014 3.1.1 The Impact of the Economy on the ADMET Testing Market, 2008-2014 3.1.2 Big Pharma Companies Are the Leading Clients for CROs 3.2 The ADMET Testing Market 2015-2025 3.2.1 What Will Drive Growth in ADMET Testing 2015-2025? 3.2.2 The ADMET Testing Market: Overall Revenue Forecast 2015-2025
4. ADMET Testing: Revenue by Segment 2015-2025 4.1 Which Market Sector Will Account for the Most Revenue from 2015-2025? 4.2 Rising Demand for Predictive ADMET Testing throughout the Decade 4.3 In Vitro ADMET Testing Market 4.3.1 In Vitro ADMET Testing: Drivers and Restraints 4.4 In Vivo ADMET Testing Market 4.4.1 In Vivo ADMET Testing: Drivers and Restraints 4.5 In Silico ADMET Testing 4.5.1 In Silico ADMET Testing: Drivers and Restraints
5. ADMET Testing: Leading Developed Markets 2015-2025 5.1 Leading National Markets for ADMET Testing 2014 5.2 ADMET Testing: Leading National Market Forecasts 2015-2025 5.3 North America as a Destination for Drug Development 5.3.1 The US: The Largest National Market for ADMET Testing 2015-2025 5.3.1.1 Government Programs to Improve ADMET in the US 5.3.2 The US: ADMET Testing Revenue Forecast 2015-2025 5.4 The Outlook for ADMET Testing in the EU5 2015-2025 5.4.1 Rewriting the Rules for Clinical Trials in the EU: Clinical Trials Regulation 5.4.2 EU5: Overall Market and Leading National Market Forecasts 2015-2025 5.4.3 Germany: Market Forecast 2015-2025 5.4.4 The UK 5.4.4.1 Overcoming Challenges in UK Clinical Trials 5.4.4.2 UK ADMET Testing Market Forecast 2015-2025 5.4.5 France: Market Forecast 2015-2025 5.4.6 Italy: Market Forecast 2015-2025 5.4.7 Spain: Market Forecast 2015-2025 5.5 Japan Is Being Challenged by Neighbouring Emerging Markets 5.5.1 Growth for ADMET Testing in Japan 2015-2025
6. ADMET: Leading Emerging Markets 2015-2025 6.1 Leading Emerging Markets for ADMET Testing 2014 6.1.1 Benefits of Conducting ADMET Testing in Emerging Markets 6.1.2 Challenges of Conducting Non-Clinical Studies in Emerging Markets 6.2 Strong Growth Forecast for Emerging ADMET Testing Markets 2015-2025 6.3 ADMET in Asia Pacific: An Emerging Market Perspective 6.3.1 China Will be the Largest Emerging Market for ADMET Testing in 2025 6.3.1.1 CRO Investments and Partnerships in China 6.3.1.2 Chinese ADMET Testing Market Forecast 2015-2025 6.3.2 India as a Hub for Clinical Trials 6.3.2.1 Indian ADMET Testing Market Forecast 2015-2025 6.3.3 South Korea 6.3.3.1 Promoting Local Drug Development in South Korea 6.3.3.2 Growth in the South Korean ADMET Market 2015-2025 6.4 Russia 6.4.1 Changing Drug Development Demands 2010-2015 6.4.2 Russian ADMET Market Forecast 2015-2025 6.5 Brazil: The Largest Market for Drug Development in Latin America 2015-2025 6.5.1 Brazilian ADMET Testing Market Forecast 2015-2025
7. Leading Companies in the ADMET Testing Industry 2014 7.1 Agilent Technologies, Inc. 7.1.1 Agilent Technologies, Inc.: Historical Revenues 2011-2014 7.1.2 Agilent Technologies, Inc. Acquires Cartagenia 7.2 Dassault Systèmes: Acquires Accelrys and forms BIOVIA 7.2.1 Accelrys: Historical Revenues 2011-2013 7.3 Cyprotex 7.3.1 Cyprotex Acquires CeeTox 7.3.2 Cyprotex Historical Revenues, 2010-2014 7.4 Bio-Rad Laboratories, Inc. 7.4.1 Bio-Rad Laboratories, Inc.: Historical Revenues 2011-2014 7.5 Quintiles 7.5.1 Expanding in Developed and Emerging Markets 7.6 Increasing Asian Regional Reach 7.6.1 CMIC Recent and Future Performance Analysis: An Asian Specialist 7.7 Charles River Laboratories Is an Expert in Pre-Clinical Services 7.8 WuXi PharmaTech 7.8.1 WuXi Acquires XenoBiotic Laboratories 7.8.2 WuXi Enters the Clinical Trial Services Market 7.9 Promega Corporation 7.10 Merck KGaA’s Acquisition of Sigma Aldrich
8. ADMET Testing Market: Industry Trends 2015-2025 8.1 Strengths and Weaknesses of the ADMET Testing Market 8.2 Opportunities and Threats in the ADMET Testing Market 8.3 ADMET Testing Market: STEP Analysis 2015-2025 8.3.1 Social Factors Affecting ADMET 2015-2025 8.3.2 Drug Developers Must Deal with Ethical Concerns for Animal Testing 8.4 Improving Technology for More Efficient Testing: High-Throughput Evaluation and In Vivo-Like Models 8.5 Economic Considerations for ADMET Testing 2015-2025 8.5.1 Demand for Predictive ADMET Testing 8.6 Political and Regulatory Developments Affecting ADMET Testing 2015-2025 8.6.1 Cutting Red Tape and Other Regulatory Developments in Drug Discovery and Development 8.6.2 Strategic Partnering for Long Term Revenue Growth 8.6.2.1 Sharing Risk Between Pharma and CROs 8.6.3 A Note on CRO Selection 8.6.3.1 Small Pharmaceutical Companies and CROs 8.6.4 CRO Consolidation is Decreasing the Number of Mid-Sized Market Players
9. Research Interviews 9.1 Interview with Dr Roustem Saiakhov, President of MultiCASE, Inc. 9.1.1 Addressing the Challenges in ADMET Testing 9.1.2 Trends in the ADMET Testing Market 9.2 Interview with Yong Huang, PhD, President and CEO of Optivia Biotechnology 9.2.1 ADMET Services at Optivia Biotechnology 9.2.2 Optivia’s Partnership with Rhenovia Pharma: CNS Drug Development 9.2.3 Optivia’s Partnership with Hurel Corporation: In Vitro-to-In Vivo Correlation 9.2.4 Challenges and Trends in Drug Discovery 9.2.5 Growth of Optivia Biotechnology in the Future? 9.3 Interview with Kristina Runeberg, Site Head of Takara Bio Europe AB 9.3.1 Acquisition of Cellectis AB 9.3.2 Addressing the Challenges in ADMET Testing 9.3.3 Trends in the ADMET Testing Market
10. Conclusions from Our Study 10.1 The World ADMET Testing Market in 2014 10.1.1 A Market Dominated by the Developed Countries 10.2 Strong Growth for the Overall Market 2015-2025 10.3 Which CROs Can Take Best Advantage of Market Growth in the Next 10 Years? 10.3.1 How Can CROs Specialise to Remain Competitive?
List of Tables Table 1.1 ADMET Testing Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2025 Table 1.2 Foreign Currency Exchange Rates: Average Exchange Rate to USD, 2013 and 2014 Table 2.1 Pharmacokinetics: Description of ADME Table 2.2 Drug Delivery Routes Table 2.3 Biosimilar Guidance Drafted Using Elements of EU Guidelines, 2008-2015 Table 2.4 Founding Members of the ICH Table 3.1 Breakdown of R&D Expenditures by Phase, 2014 Table 3.2 CRO Services Revenue by Customer Type, 2014 Table 3.3 ADMET Testing Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2025 Table 4.1 ADMET Testing Submarket Revenue ($bn) and Market Shares (%), 2014, 2019, and 2025 Table 4.2 ADMET Testing Submarket Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2025 Table 4.3 In Vitro ADMET Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2025 Table 4.4 In Vivo ADMET Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2025 Table 4.5 In Silico ADMET Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2025 Table 5.1 World ADMET Testing Market by National Market: Revenue ($bn) and Market Share (%), 2014 Table 5.2 ADMET Testing Market Forecast by Country: Revenue ($bn), AGR (%) and CAGR (%), 2015-2025 Table 5.3 ADMET Testing: Market Shares by Country, 2014, 2019 and 2025 Table 5.4 US ADMET Testing Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2025 Table 5.5 EU5 ADMET Testing Market by Country, 2014 Table 5.6 EU5 ADMET Testing Market Forecast by Country: Revenue ($bn), AGR (%) and CAGR (%), 2015-2025 Table 5.7 German ADMET Testing Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2025 Table 5.8 UK ADMET Testing Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2025 Table 5.9 French ADMET Testing Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2025 Table 5.10 Italian ADMET Testing Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2025 Table 5.11 Spanish ADMET Testing Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2025 Table 5.12 Japanese ADMET Testing Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2025 Table 6.1 Leading Emerging Markets for ADMET Testing, 2014 Table 6.2 Population Statistics in BRIC Nations, May 2015 Table 6.3 English Proficiency in Emerging Markets, 2014 Table 6.4 ADMET Testing Market Forecast in Emerging Markets: Revenue ($bn), AGR (%) and CAGR (%), 2015-2025 Table 6.5 Chinese ADMET Testing Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2025 Table 6.6 Indian ADMET Testing Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2025 Table 6.7 South Korean ADMET Testing Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2025 Table 6.8 Russian ADMET Testing Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2025 Table 6.9 Brazilian ADMET Testing Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2015-2025 Table 7.1 Selected Companies in the ADMET Testing Industry, 2015 Table 7.2 Selected Agilent Technologies MS Products, 2015 Table 7.3 Agilent Technologies: Revenue ($bn), AGR (%) and CAGR (%), 2011-2014 Table 7.4 Agilent Technologies: Revenue ($bn) and Revenue Share (%) by Sector, 2013 and 2014 Table 7.5 Accelrys: Revenue ($bn), AGR (%) and CAGR (%), 2011-2013 Table 7.6 Cyprotex ADME & PK Services, 2015 Table 7.7 Cyprotex In Vitro Toxicology Services, 2015 Table 7.8 Cyprotex In Silico Services, 2015 Table 7.9 Cyprotex: Revenue ($bn and £bn), AGR (%) and CAGR (%), 2011-2014 Table 7.10 Bio-Rad Laboratories: Revenue ($bn), AGR (%) and CAGR (%), 2011-2014 Table 7.11 Quintiles: Service Revenue ($bn), AGR (%) and CAGR (%), 2010-2014 Table 7.12 CMIC: CRO Service Revenue ($bn and ¥bn), AGR (%) and CAGR (%), 2011-2014 Table 7.13 Charles River Laboratories: Revenue ($bn) and Revenue Share (%) by Sector, 2013 and 2014 Table 7.14 WuXi PharmaTech: Revenue ($bn) and CAGR (%) by Sector, 2012-2014 Table 8.1 ADMET Testing Market: Strengths and Weaknesses, 2015 Table 8.2 ADMET Testing Market: Opportunities and Threats, 2015 Table 8.3 ADMET Testing Market: STEP Analysis, 2015 Table 10.1 ADMET Testing Market by Sector: Revenue ($bn), CAGR (%) and Market Share (%), 2014, 2019 & 2025
List of Figures Figure 2.1 Drug Design Process Figure 2.2 ADMET Parameters Figure 3.1 Breakdown of Pharma Clinical Spending by Phase, 2014 Figure 3.2 CRO Services Revenue by Customer Type, 2014 Figure 3.3 ADMET Testing Market: Drivers and Restraints, 2015-2025 Figure 3.4 ADMET Testing Market Revenue ($bn) Forecast, 2015-2025 Figure 4.1 ADMET Testing Market Revenue ($bn) by Submarket, 2014, 2019 and 2025 Figure 4.2 ADMET Testing Submarket Shares (%), 2014 Figure 4.3 ADMET Testing Submarket Shares (%), 2019 Figure 4.4 ADMET Testing Submarket Shares (%), 2025 Figure 4.5 ADMET Testing Market Revenue ($bn) Forecast by Submarket, 2015-2025 Figure 4.6 In Vitro ADMET Revenue ($bn) Forecast, 2015-2025 Figure 4.7 In Vitro ADMET: Drivers and Restraints, 2015-2025 Figure 4.8 In Vivo Submarket Revenue ($bn) Forecast, 2015-2025 Figure 4.9 In Vivo ADMET: Drivers and Restraints, 2015-2025 Figure 4.10 In Silico Testing Submarket Revenue ($bn) Forecast, 2015-2025 Figure 4.11 In Silico Submarket: Drivers and Restraints, 2015-2025 Figure 5.1 World ADMET Testing Market by National Market: Market Share (%), 2014 Figure 5.2 World ADMET Testing Market by National Market: Market Share (%), 2019 Figure 5.3 World ADMET Testing Market by National Market: Market Share (%), 2025 Figure 5.4 US ADMET Testing Market Revenue ($bn) Forecast, 2015-2025 Figure 5.5 EU5 ADMET Testing Market Share (%) by Country, 2014 Figure 5.6 EU5 ADMET Testing Market Revenue ($bn) Forecast, 2015-2025 Figure 5.7 German ADMET Testing Market Revenue ($bn) Forecast, 2015-2025 Figure 5.8 UK ADMET Testing Market Revenue ($bn) Forecast, 2015-2025 Figure 5.9 French ADMET Testing Market Revenue ($bn) Forecast, 2015-2025 Figure 5.10 Italian ADMET Testing Market Revenue ($bn) Forecast, 2015-2025 Figure 5.11 Spanish ADMET Testing Market Revenue ($bn) Forecast, 2015-2025 Figure 5.12 Japanese ADMET Testing Market Revenue ($bn) Forecast, 2015-2025 Figure 6.1 Leading Emerging Markets for ADMET Testing by Market Share (%), 2014 Figure 6.2 Cost Savings Available for Clinical Trials in Emerging Markets, 2014 Figure 6.3 Relative Competence in English in Emerging Markets, 2012 Figure 6.4 ADMET Testing: Emerging Market Revenue ($bn) Forecasts, 2015-2025 Figure 6.5 Chinese ADMET Testing Market Revenue ($bn) Forecast, 2015-2025 Figure 6.6 Indian ADMET Testing Market Revenue ($bn) Forecast, 2015-2025 Figure 6.7 South Korean ADMET Testing Market Revenue ($bn) Forecast, 2015-2025 Figure 6.8 Russian ADMET Testing Market Revenue ($bn) Forecast, 2015-2025 Figure 6.9 Brazilian ADMET Testing Market Revenue ($bn) Forecast, 2015-2025 Figure 7.1 Agilent Technologies: Revenue ($bn) and AGR (%), 2011-2014 Figure 7.2 Agilent Technologies: Revenue Share (%) by Sector, 2014 Figure 7.3 Accelrys: Revenue ($bn) and AGR (%), 2011-2013 Figure 7.4 Cyprotex: Revenue ($bn) and AGR (%), 2011-2014 Figure 7.5 Bio-Rad Laboratories: Revenue ($bn) and AGR (%), 2011-2014 Figure 7.6 Quintiles: Service Revenue ($bn) and AGR (%), 2010-2014 Figure 7.7 CMIC: CRO Service Revenue ($bn) and AGR (%), 2011-2014 Figure 7.8 Charles River Laboratories Clinical Trials: Revenue ($bn) by Sector, 2013 and 2014 Figure 7.9 WuXi PharmaTech: Revenue ($bn) by Sector, 2012-2014 Figure 10.1 ADMET Testing Market Revenue ($bn) by Sector, 2014, 2019 & 2025
AbD Serotec (now part of Bio-Rad Laboratories) ACEA Biosciences Aegis Analytical Corp Agenzia Italiana del Farmaco Agência Nacional de Vigilância Sanitária (ANVISA) Agilent Technologies Albany Molecular Research Apredica, LLC Associação Brasileira de CROs Association of Clinical Trial Organisations (ACTO) [Russia] AstraZeneca Bayer BD Biosciences Beckman Coulter Bio-Rad Laboratories BIOVIA Boehringer Ingelheim Caliper Life Sciences Cambridge Cell Networks Catalent Pharma Solutions Catalina Health (now part of InVentiv Health) Celerion Cellartis Cellectis AB Cellumen Celsis International Charles River Laboratories ChemSW Chinese Ministry of Commerce Clinipace Worldwide ClinStar (now part of PRA Health Sciences) CMIC Holdings Council for Economic Defense [Brazil] Cromos Pharma CROMSOURCE Cyprotex Department of Health and Human Services [US] EF Education First Entelos Holdings Environmental Protection Agency [US] EPS Holdings, Inc., formerly EPS Corporation European Commission European Medicines Agency (EMA) Fish and Wildlife Service [US] Food and Drug Administration (FDA) [US] Frontage Laboratories GCP ClinPlus I3 Research (now part of InVentiv Health) ICON plc INC Research International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) InVentiv Health Harlan Laboratories (now part of Huntingdon Life Sciences) Helmholtz Association Helmholtz Zentrum München (German Research Center for Environmental Health) Hisun Pharmaceuticals Hospital Italiano of Buenos Aires Huntingdon Life Sciences JCL Bioassay Corporation (now part of CMIC) Kendle (now part of INC Research) Kforce Clinical Research (now part of InVentiv Health) Korea Drug Development Fund Korea Food and Drug Administration (KFDA) Korea National Enterprise for Clinical Trials L'Agence Nationale de Sécurité du Médicament (l’ANSM) Les Entreprises du Medicament (LEEM) Life Technologies Corporation LSK Malaysian Biotechnology Corporation Medicines and Healthcare Products Regulatory Agency (MHRA) [UK] Merck & Co. Merck KGaA Mitsubishi Gas Chemical Company, Inc. MultiCASE Nagoya University National Association for Biomedical Research [US] National Cancer Institute (NCI) [US] National Center for Advancing Translational Sciences [US] National Centre for Computational Toxicology [US} National Enterprise for Clinical Trials [South Korea] National Human Genome Research Institute [US] National Institute of Environmental Health Sciences [US] National Institutes of Health (NIH) [US] National Toxicology Program [US] New England Antivivisection Society New York Stock Exchange Noray Bioinformatics Novartis Novotech Oncobiologics Optivia Biotechnology Organovo Holdings, Inc. Parexel PerkinElmer Pharmaron PharmaNet Development Group (now part of InVentiv Health) PRA Health Sciences Prodia Clinical Laboratory Promega Corporation Proteomics ProTrials Research Quintiles ReSearch Pharmaceutical Services (now part of PRA Health Sciences) Rosa & Co Russian Ministry of Public Health Samsung Sekisui Medical Co. Seoul National University Hospital Clinical Trials Center Shanghai Clinical Research Center to ShangPharma Sigma-Aldrich Simulations Plus Sugi Medical Co. (now part of CMIC) Taconic Biosciences Takara Bio Europe AB Takara Bio Inc Tecan Group Thermo Fisher Scientific Tigermed Consulting VelQuest Vialis Vietnam Ministry of Health Administration of Science, Technology and Training (ASST) West Coast Clinical Trials World Health Organization (WHO) WuXi PharmaTech Xceleron XenoBiotic Laboratories XenoTech (now part of Sekisui) Yungjin Pharmaceutical Zhejiang Jiang Yuan Tang Biotechnology Co., Ltd
Download sample pages
Complete the form below to download your free sample pages for Pharma ADMET Testing: World Industry and Market Prospects 2015-2025
Download sample pages
Complete the form below to download your free sample pages for Pharma ADMET Testing: World Industry and Market Prospects 2015-2025
Visiongain’s reports are based on comprehensive primary and secondary research. Those studies provide global market forecasts (sales by drug and class, with sub-markets and leading nations covered) and analyses of market drivers and restraints (including SWOT analysis) and current pipeline developments. To find out more about our reports methodology, please email sara.peerun@visiongain.com
Win a Free Visiongain Pharma report – ‘Like’ our Pharma Facebook page with the link below and enter into our raffle to win a free, unlocked Visiongain report, choosing your relevant report from our reports selection.
The global market for dermatological drugs is ascending and has made significant gains in skin treatments. The players in the dermatological drugs market are striving to tap the opportunities that this market offers.
Visiongain Publishes Biological API Manufacturing Services Market Report 2021-2031
Demand in the early years of the forecast period will come from multinational biotech looking to sign deals with Indian companies and take advantage of the cheaper costs of production for the emerging market.
The growth can be attributed to the rising prevalence of respiratory diseases, growing awareness for respiratory diseases, and innovations in respiratory and anesthesia devices. However, unfavourable reimbursement policies and lack of patient adherence in respiratory diseases are some of the factors restraining the growth of the anesthesia and respiratory devices market.
Factors such as rise in the prevalence of the infectious and bacterial diseases and active participation of government in vaccine development are driving the growth of this market. While high cost of vaccine development is the key factor emerging as a growth barrier over years in this market.
Visiongain Pharma
Visiongain Pharma
Visiongain Pharma
